37 articles available

Provider review

CoreAge Rx nonhormonal menopause review: paroxetine and the actual treatment goal

The advertised oral paroxetine offer, its off-label menopause wording, starting price, and the clinical questions a product page cannot settle.

Comparison

Best nonhormonal menopause care options to compare, with clear limits

A disclosed commercial first position for CoreAge, followed by a comparison of provider scope, exact medicines, follow-up responsibilities and cost units.

Provider review

Midi nonhormonal menopause review: what a care-plan visit includes

Midi explicitly discusses nonhormonal options. Its consultation scope, public treatment summaries and insurance rules still need to be read separately.

Provider review

Evernow nonhormonal menopause review: medicine choices and ongoing care

Official paroxetine and Veozah pages confirm the nonhormonal scope. Check the exact prescription, current safety record and care-access costs before interpreting the offer.

Guide

Non-estrogen medication for hot flashes: understand the treatment families

Separate antidepressant medicines, neurokinin-targeted treatments, other prescriptions and evidence-based non-drug support without ranking them for an individual.

Guide

Fezolinetant and liver monitoring: understand the responsibility behind the tests

What Veozah's current boxed warning adds to a hot-flash treatment discussion, and why a laboratory order needs a clear review and response process.

Guide

Lynkuet vs Veozah: a guide to comparing the evidence

Compare the questions each product raises, read the trial limits and prepare for a discussion about treatment and follow-up.

Guide

Prepare a nonhormonal menopause visit around the result that matters to you

Bring symptom priorities, previous treatment experience and practical follow-up questions without trying to choose a prescription from an online checklist.

Provider review

Alloy nonhormonal menopause review: the product behind the approval claim

Alloy offers paroxetine for hot flashes. Its advertised strength, approval wording and conflicting supply descriptions need to be read together.

Provider review

Gennev nonhormonal menopause review: separate the doctor’s proposal from lifestyle support

Gennev explicitly offers nonhormonal prescriptions alongside dietitian and lifestyle services. Their purposes, evidence and costs should remain distinguishable.

Provider review

MyMenopauseRx nonhormonal menopause review: a named medicine brings additional responsibilities

MyMenopauseRx lists fezolinetant among its options. That specific offer makes the current liver-safety record and responsibility for follow-up important parts of the conversation.

Provider review

Pandia Health nonhormonal menopause review: two named options within a larger care offer

Pandia lists paroxetine and Veozah alongside hormone medicines. The menu, clinical membership and pharmacy transaction answer different questions.

Provider review

Stella nonhormonal menopause review: clinical treatment and app support have different roles

Stella’s US service explicitly includes nonhormonal options, while its app supplies coaching and educational support. One does not establish the evidence or availability of the other.

Provider review

Wisp nonhormonal menopause review: local dryness care is not a hot-flash medicine offer

Wisp has a menopause consultation and a specific hormone-free vaginal moisturizer listing. Those records support different claims and different purchase questions.

Provider review

Joi nonhormonal menopause review: a relevant clinic with an unresolved treatment menu

Joi has an actual menopause clinical service, but the reviewed program centers on hormones. Its wellness language does not confirm a specific nonhormonal hot-flash prescription.

Provider review

FOLX nonhormonal menopause review: clinical care, community and membership are separate

FOLX explicitly offers nonhormonal menopause medicines within LGBTQIA+ care. Its membership, clinical visits and community support should not be treated as one treatment or price.

Provider review

Maven Clinic nonhormonal menopause review: what the two-visit package includes

Maven’s direct Hormone Care offer names nonhormonal medicine families. Its one-time package has defined consultation and messaging limits, with prescriptions and later care separate.

Product review

Veozah review: hot-flash evidence with a liver-safety responsibility

Read the exact fezolinetant tablet record, the placebo comparison and the practical responsibilities that accompany its boxed warning.

Product review

Lynkuet review: original approval evidence and the newer seizure warning

Elinzanetant has a defined hot-flash indication, a placebo-controlled evidence base and current safety information beyond its launch announcement.

Product review

Brisdelle review: the specific paroxetine capsule behind a hot-flash approval

A low-strength capsule has a defined menopausal indication, distinct trial findings and SSRI precautions that a generic ingredient reference can obscure.

Provider review

Allara nonhormonal menopause review: symptom care, nutrition and plan-price differences

Allara includes menopause in its clinical scope, but its broader care program, treatment evidence and conflicting price displays require separate reading.

Provider review

Hello Alpha nonhormonal menopause review: separate the symptom menu from the prescription

The service names antidepressants and gabapentin, while its local-cream wording, membership allowance and refill terms need close attention.

Provider review

Myla Health nonhormonal menopause review: a UK discussion with explicit follow-up boundaries

Myla’s consultation, NHS handoff limits and responsibility for outside investigations matter when hormone avoidance is only the starting question.

Provider review

Newson Clinic nonhormonal menopause review: what the consultation page actually promises

A UK clinic explicitly includes nonhormonal options in discussion; that statement still leaves the medicine, jurisdiction and complete care costs to identify.

Provider review

Mass General Brigham nonhormonal menopause review: coordinating a regional symptom assessment

The Menopause and Midlife Clinic offers an actual clinical route; its breadth should not be confused with a verified medication menu or an all-inclusive price.

Provider review

Penn Medicine nonhormonal menopause review: what needs current confirmation

Our September 29 service description is historical. Current scope, appointment routing and eligibility need confirmation before arranging care.

Provider review

Duke Health nonhormonal menopause review: define the hot-flash goal before interpreting the drug family

Duke discusses low-dose antidepressants for hot flashes, night sweats and sleep disturbance. The family name does not identify a prescription, diagnose depression or settle the safety review.

Provider review

Cleveland Clinic nonhormonal menopause review: hot flashes and vaginal discomfort are different goals

Cleveland describes nonhormonal hot-flash medicines and over-the-counter vaginal lubricants. These are different treatment discussions, with individual medication decisions separate from a shared appointment.

Provider review

Mayo Clinic nonhormonal menopause review: choose the consultation goal before naming a treatment

Mayo’s Minnesota clinic separates menopause, sexual-health and cancer-survivorship consultations. Nonhormonal options are a documented discussion topic, not one medicine for every concern.

Provider review

Johns Hopkins nonhormonal menopause review: a coordinated assessment comes before the medication category

Hopkins offers referral-based menopause care and discussion of several treatment approaches. Its public clinic page does not identify a nonhormonal medicine or promise a particular remote prescription.

Provider review

Mount Sinai nonhormonal menopause review: symptom research is different from a treatment offer

Mount Sinai documents clinical menopause care and research about differences in hot flashes. Those records do not identify an exact nonhormonal prescription or prove that a newer medicine is available there.

Provider review

Northwestern Medicine nonhormonal menopause review: therapy roles should follow the concern

Northwestern lists nonhormonal options, pelvic-floor therapy and talk therapy for specified concerns. A broad menu does not make every form of support a proven treatment for hot flashes.

Provider review

UCLA Health nonhormonal menopause review: sleep concerns need their own treatment question

UCLA’s multidisciplinary service includes sleep, cognition and mood. Those assessment areas do not establish a named nonhormonal prescription or turn a hot-flash medicine into an insomnia treatment.

Provider review

Stanford Health Care nonhormonal menopause review: a named option still needs its own safety plan

Stanford names fezolinetant, gabapentin and antidepressants. The current fezolinetant label adds an essential boundary to that treatment menu: liver risk, contraindications and accountable monitoring.

Provider review

University of Utah Health nonhormonal menopause review: a broad care menu needs a defined outcome

Utah combines nonhormonal therapies with behavioral, sexual-health and wellness services. A named program is not proof that every listed approach treats hot flashes or fits every medical history.

Guide

Paroxetine’s Menopause Trials: Reading Hot-Flash and Sleep Outcomes Together

Two placebo-controlled trials support a specific hot-flash benefit, while a secondary analysis found modest improvements in symptom-attributed awakenings and sleep duration. Those findings answer a different question from fezolinetant’s research program.

Guide

SKYLIGHT 1: Fezolinetant’s Symptom Effects and Evolving Liver-Safety Evidence

The 527-participant trial established a placebo-adjusted symptom benefit over 12 weeks. Its findings answer a different question from paroxetine’s sleep analyses—and must now be read alongside VEOZAH’s boxed liver warning.